Louisville, Kentucky-based Humana Inc. (HUM) provides medical and specialty insurance products in the United States. The company has a market cap of $50.7 billion and operates in two segments, Insurance and CenterWell, and offers individual Medicare Advantage products, including health insurance benefits, wellness programs, chronic care management, and care coordination. HUM is expected to release its Q3 2026 earnings on Friday, November 6, before the market opens.
Ahead of the event, analysts expect the company's loss per share to be $1.03 on a diluted basis, down 131.8% from $3.24 in the year-ago quarter. The company has exceeded Wall Street's EPS estimates in each of its last four quarters, which is impressive.
More News from Barchart
For fiscal 2026, analysts project the company's EPS to be $9.04, down 47.3% from $17.14 in fiscal 2025. However, its EPS is expected to rise by roughly 77.4% year over year (YoY) to $16.02 in fiscal 2027.
HUM stock has surged 43.6% over the past 52 weeks, outpacing the S&P 500 Index's ($SPX) 13% rise and the State Street Healthcare Select Sector SPDR ETF's (XLV) 22.8% rise during the same time frame.
On Oct. 13, HUM announced a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a part of BlackRock, Inc. (BLK), to manage and operate nearly 150 CenterWell Senior Primary Care clinics that fall under joint ventures owned by funds affiliated with WCAS and CenterWell. This venture is expected to provide additional growth capital and greater financial flexibility for Humana, as well as support future growth opportunities for CenterWell. BlackRock is one of the world's leading investment management firms, marking this the second transaction with Humana this year, and also forming a strategic alliance to manage future clinics and healthcare facilities.
Analysts are somewhat bullish on HUM, with the stock having a "Moderate Buy" rating overall. Among the 26 analysts covering the stock, 15 are recommending a "Strong Buy," one suggests a "Moderate Buy," nine recommend a "Hold," and one suggests a "Strong Sell." HUM's average analyst price target of $463.12 indicates an 11% upside from current levels.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
